ARTV Earnings & Financial Statements
Artiva Biotherapeutics, Inc.
$5.91
-$0.38(-6.04%)
35
Overall
60
Value
18
Tech
28
Quality
Market Cap
$288.94M
Volume
706.13K
52W Range
$2.71 - $14.53
Target Price
$35.80
ARTV earnings and financial statements: Artiva Biotherapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ARTV Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | - | $251.0K | $33.49M | $4.93M |
| Operating income | -$89.81M | -$67.28M | -$30.67M | -$59.83M |
| EBITDA | -$81.56M | -$63.19M | -$26.38M | -$57.58M |
| Net income | -$83.86M | -$65.37M | -$28.72M | -$58.79M |
| EPS (diluted) | $-3.43 | $-5.81 | $-35.78 | $-76.67 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $130.94M | $209.58M | $105.11M | $133.05M |
| Total liabilities | $20.97M | $22.94M | $50.72M | $57.34M |
| Shareholders’ equity | $109.97M | $186.64M | $54.40M | $75.72M |
| Cash and equivalents | $26.70M | $40.23M | $53.50M | $102.53M |
| Long-term debt | $7.88M | $10.61M | $13.32M | $15.96M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$76.75M | -$55.03M | -$47.43M | -$50.83M |
| Capital expenditure | -$2.59M | -$642.0K | - | - |
| Free cash flow | -$79.34M | -$55.67M | -$50.69M | -$57.13M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARTV | $5.91 | -6.0% | 706.13K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Artiva Biotherapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW